Giguère Vincent, Gallant Maxime A, de Brum-Fernandes Artur J, Parent Jean-Luc
Division of Rheumatology, Faculty of Medecine and Clinical Research Center, Université de Sherbrooke, Sherbrooke, Quebec, Canada J1H 5N4.
Eur J Pharmacol. 2004 Jun 21;494(1):11-22. doi: 10.1016/j.ejphar.2004.04.041.
Prostacyclin activation of prostanoid IP receptors may result in pain sensation, inflammatory responses, inhibition of platelet aggregation, and vasodilation in vascular tissue. The prostanoid IP receptor is a G-protein-coupled receptor. In the present study, we investigated the determinants responsible, at least in part, for the prostacyclin receptor (IP) dimerization/oligomerization. Using co-immunoprecipitation of differentially tagged IP expressed in COS-7 cells, we demonstrate that IP can form dimers and oligomers. Treatment of IP-expressing cells with the stable agonist carbaprostacyclin failed to alter the ratios of oligomeric/dimeric/monomeric forms of the receptor, suggesting that IP dimerization/oligomerization is an agonist-independent process. The reducing agents dithiothreitol and 2-mercaptoethanol were highly efficient in converting the receptor from its oligomeric form to the monomeric state, indicating the involvement of disulfide bonds in IP oligomerization. Immunoblotting of the osteoblastic MG-63 cell line lysates with an anti-IP specific antibody revealed the presence of endogenous IP oligomers which were converted to dimers and monomers upon treatment with dithiothreitol. Individual substitutions of the four extracellular IP Cys residues (Cys(5), Cys(92), Cys(165) and Cys(170)) for Ser resulted in greatly decreased receptor protein expression in COS-7 cells. The C92-170S double mutant showed receptor protein expression level similar to the individual mutants. However, expression of the C92-165S and C165-170S mutants was drastically reduced, suggesting that there was formation of disulfide bonds between Cys(5) and Cys(165), and between Cys(92) and Cys(170). The Cys receptor mutants showed altered oligomer/dimer/monomer ratios. Dimerization/oligomerization likely occurs intracellularly since these Cys receptor mutants could still form dimers/oligomers despite their lack of expression at the cell surface.
前列环素激活类前列腺素 IP 受体可能会导致疼痛感觉、炎症反应、抑制血小板聚集以及血管组织中的血管舒张。类前列腺素 IP 受体是一种 G 蛋白偶联受体。在本研究中,我们调查了至少部分负责前列环素受体(IP)二聚化/寡聚化的决定因素。利用在 COS-7 细胞中表达的差异标记 IP 的免疫共沉淀技术,我们证明 IP 可以形成二聚体和寡聚体。用稳定激动剂卡前列环素处理表达 IP 的细胞未能改变受体的寡聚体/二聚体/单体形式的比例,这表明 IP 二聚化/寡聚化是一个不依赖激动剂的过程。还原剂二硫苏糖醇和 2-巯基乙醇能高效地将受体从其寡聚形式转化为单体状态,表明二硫键参与了 IP 的寡聚化。用抗 IP 特异性抗体对成骨细胞 MG-63 细胞系裂解物进行免疫印迹分析,发现存在内源性 IP 寡聚体,在用二硫苏糖醇处理后其转化为二聚体和单体。将四个细胞外 IP 半胱氨酸残基(Cys(5)、Cys(92)、Cys(165) 和 Cys(170))逐个替换为丝氨酸,导致 COS-7 细胞中受体蛋白表达大幅下降。C92-170S 双突变体显示出与单个突变体相似的受体蛋白表达水平。然而,C92-165S 和 C165-170S 突变体的表达急剧下降,这表明在 Cys(5) 和 Cys(165) 之间以及 Cys(92) 和 Cys(170) 之间形成了二硫键。半胱氨酸受体突变体显示出寡聚体/二聚体/单体比例的改变。二聚化/寡聚化可能发生在细胞内,因为尽管这些半胱氨酸受体突变体在细胞表面缺乏表达,但它们仍然可以形成二聚体/寡聚体。